Multi-dimensional Signatures for Precisely Predicting the Response and Prognosis of Lung Cancer Patients
- Conditions
- PrognosisResponse
- Registration Number
- NCT04980352
- Lead Sponsor
- Wuhan Union Hospital, China
- Brief Summary
This study aims to determine the clinical effectiveness of multi-dimensional signatures in predicting response and prognosis of lung cancer patients. The study is a multi-center perspective research of treatment planning for patients with lung cancer. To characterize clinical effectiveness, the progression-free survival (PFS) and overall survival (OS) impacts of multi-dimensional signatures will be estimated.
- Detailed Description
Multi-dimensional signatures, including NGS-based genotyping, and other essential detections such as immunohistochemistry (IHC), provides an opportunity to improve outcomes for patients by tailoring treatments to each individual's genomic profile. This is a multi-center single arm research study integrating multi-dimensional signatures into clinical decision-making for patients with lung cancer. The clinical effectiveness of multi-dimensional signatures is unknown in the real-world of clinics. To identify a counterfactual for Pred-lung approach, matching methods combined with administrative healthcare data will be used. The survival impacts of Pred-lung approach compared to usual care in matched controls will then be estimated.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Patients with locally-advanced or metastasis lung cancer
- Life expectancy > 3 months
- Age at diagnosis <18
- refuse to enroll
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS through study completion, an average of 6 months Progression-free survival
- Secondary Outcome Measures
Name Time Method OS through study completion, an average of 1 year Overall survival
Trial Locations
- Locations (1)
Wuhan Union Hospital
🇨🇳Wuhan, Hubei, China